Prostate最新文献

{"title":"A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.","authors":"Koichiro Kurokawa, Satoshi Yamamoto, Yasutaka Yamada, Kodai Sato, Takuya Tsujino, Shinpei Saito, Yuki Yoshikawa, Kazuki Nishimura, Tatsuo Fukushima, Ko Nakamura, Takayuki Arai, Hiroaki Sato, Kosuke Higuchi, Akinori Takei, Manato Kanesaka, Keisuke Ando, Sangjon Pae, Sanji Kanaoka, Nobushige Takeshita, Kei Yoneda, Daichi Hino, Takaaki Tamura, Tomokazu Sazuka, Yusuke Imamura, Kazuo Mikami, Kazuyoshi Nakamura, Satoshi Fukasawa, Akira Kurozumi, Yukio Naya, Maki Nagata, Atsushi Komaru, Toyofusa Tobe, Noriyuki Suzuki, Haruhito Azuma, Shinichi Sakamoto","doi":"10.1002/pros.70171","DOIUrl":"https://doi.org/10.1002/pros.70171","url":null,"abstract":"<p><strong>Background: </strong>Metastatic hormone-sensitive prostate cancer (mHSPC) remains clinically heterogeneous despite upfront treatment intensification. The commonly used CHAARTED high-volume and LATITUDE high-risk criteria stratify metastatic burden but do not explicitly incorporate Eastern Cooperative Oncology Group (ECOG) performance status (PS). We developed and internally assessed a simple bedside prognostic score integrating PS with aggressive metastatic burden in a real-world mHSPC cohort.</p><p><strong>Methods: </strong>We retrospectively identified consecutive patients with histologically confirmed prostate adenocarcinoma who initiated first-line androgen deprivation therapy (ADT)-based systemic therapy for mHSPC between January 2014 and May 2025. Metastases were assessed primarily by conventional imaging (bone scintigraphy and computed tomography [CT]). The PS-Metastatic Burden score (0-2) assigned 1 point each for ECOG PS ≥ 1 and for aggressive metastatic burden defined as bone scan extent of disease (EOD) ≥ 3 and/or liver metastasis. The primary endpoint was overall survival (OS). Model fit and discrimination were compared with CHAARTED and LATITUDE using Akaike information criterion (AIC) and Harrell's concordance index (C-index) in a common complete-case dataset.</p><p><strong>Results: </strong>Among 886 patients (median follow-up 36.9 months), 218 deaths occurred. Score distribution was 0/1/2 points in 592 (66.8%)/257 (29.0%)/37 (4.2%). OS was clearly separated across groups (log-rank p < 0.001): median OS was not reached for score 0 during follow-up; it was 49.0 months for score 1, and 37.3 months for score 2. In complete cases (n = 869; deaths = 211), hazard ratios versus score 0 were 2.16 (95% confidence interval [CI] 1.62-2.87) for score 1 and 3.08 (95% CI 1.87-5.08) for score 2 (both p < 0.001). The PS-Metastatic Burden score showed superior performance (AIC 2513.2; C-index 0.600) compared with CHAARTED and LATITUDE; adding PS to those frameworks improved performance modestly but remained inferior. Upfront androgen receptor pathway inhibitor (ARPI) use was lower in ECOG PS ≥ 1 than PS 0 (38.4% vs 60.8%; p < 0.001), and best supportive care initiation or death increased stepwise across score groups (21.3%, 37.2%, 51.4%).</p><p><strong>Conclusions: </strong>A two-factor bedside score integrating host reserve and aggressive metastatic burden provides pragmatic prognostic stratification for real-world mHSPC in the upfront ARPI era and offers information beyond CHAARTED/LATITUDE. External validation is warranted.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Saturation Biopsy Still a Viable Alternative to Fusion Biopsy in the Era of Multiparametric MRI? A Comparative Analysis in Patients With Prior Negative Biopsy.","authors":"Arda Taşkın Taşkıran, Yusuf Şenoğlu","doi":"10.1002/pros.70169","DOIUrl":"https://doi.org/10.1002/pros.70169","url":null,"abstract":"<p><strong>Background: </strong>We aimed to compare the diagnostic accuracy of transrectal ultrasound (TRUS)-guided saturation biopsy (SB) and multiparametric MRI (mpMRI)-TRUS fusion-guided combined biopsy (CB) in patients with prior negative prostate biopsies.</p><p><strong>Methods: </strong>We retrospectively analyzed data from 160 patients who underwent transrectal prostate biopsy between January 2014 and March 2021. All had at least one prior negative biopsy. 80 patients underwent SB with a 20-core TRUS-guided approach. The remaining 80 patients, with mpMRI-detected PIRADS ≥ 3 lesions, underwent CB including 12-core systematic plus 2-4 targeted cores per lesion. Prostate cancer and clinically significant prostate cancer (csPCa) detection rates, and clinical parameters were compared between groups.</p><p><strong>Results: </strong>The groups had no statistically significant differences in baseline characteristics. The PCa detection rate was 20% in the CB group and 16.3% in the SB group (p = 0.682). csPCa detection rates were also similar: 11.3% in the CB cohort and 7.5% in the SB cohort (p = 0.589). Notably, the CB subgroup with PI-RADS ≥ 4 lesions had a significantly higher csPCa detection rate (28.6%) than SB group (7.5%) (p = 0.016). Patients diagnosed with PCa had significantly lower free PSA and free/total PSA ratios (p < 0.05). Complication rates were low and similar in both groups.</p><p><strong>Conclusions: </strong>CB demonstrates the highest diagnostic yield for detecting csPCa, particularly in patients with PI-RADS ≥ 4 lesions. However, in resource-limited settings lacking mpMRI, systematic saturation biopsy remains a viable, safe, and effective alternative. PSA derivatives may serve as complementary tools to refine biopsy decisions.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of Machine Learning Models for Predicting Prostate Cancer in Biopsy Candidates Using Prostate-Specific Antigen, Magnetic Resonance Imaging, and Hematologic Parameters.","authors":"Deniz Noyan Özlü, Yusuf Arıkan, Büşra Emir, Ali Ayten, Ubeyd Sungur, Mithat Ekşi, Hakan Polat, Serdar Karadağ, Alper Bitkin","doi":"10.1002/pros.70168","DOIUrl":"https://doi.org/10.1002/pros.70168","url":null,"abstract":"<p><strong>Introduction: </strong>Prostate-specific antigen (PSA) alone is insufficient for the diagnosis of prostate cancer (PCa), particularly within the gray zone range of 4-10 ng/mL. Multiparametric magnetic resonance imaging (mpMRI), although widely used, has notable limitations in the diagnostic pathway. The aim of this study was to develop a biopsy prediction model by evaluating multiple machine learning (ML) algorithms incorporating PSA-related variables, mpMRI findings, and hematologic parameters.</p><p><strong>Materials and methods: </strong>This study included patients who underwent either systematic biopsy or combined biopsy (systematic plus fusion) based on mpMRI findings and had pre-biopsy PSA levels ≤ 10 ng/mL between 2017 and 2024 at our center. Laboratory findings, mpMRI results, and prostate biopsy outcomes were recorded. Based on the pathological evaluation of biopsy specimens, the patients were divided into two groups: those without malignancy (Group 1) and those with malignancy (Group 2). To develop a useful model for prediction, five ML techniques were applied: logistic regression, random forest (RF), extra trees, extreme gradient boosting (XGBoost) classifier, and light gradient-boosting machine classifier.</p><p><strong>Results: </strong>There were 1223 patients (84.5%) in Group 1 and 225 patients (15.5%) in Group 2. The model with the best accuracy was XGBoost, with a sensitivity of 94.74% and a specificity of 100% on the test data set. For the RF model, sensitivity and specificity on the test data set were determined to be 78.95% and 100%, respectively. The area under the curve (AUC) values for XGBoost and RF were 0.97 and 0.89, respectively. According to the permutation feature importance analysis, the three most influential variables were free/total PSA, Prostate Imaging-Reporting and Data System Score 4, and platelet-to-lymphocyte ratio.</p><p><strong>Conclusion: </strong>XGBoost and RF models demonstrated excellent performance, with high AUC values. To generalize the results, it is necessary to confirm the accuracy of ML models through external validation in different populations.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":""},"PeriodicalIF":2.5,"publicationDate":"2026-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147583019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Comparative Study of the Global Burden of Prostate Cancer (1990-2021): Emphasis on the Disparities Between the United States and China.","authors":"Junxiong Li, Yupeng Wu, Jian Hou, Haolin Liu, Yumin Wang, Feng Zhang, Peng Gu, Xiaodong Liu","doi":"10.1002/pros.70104","DOIUrl":"10.1002/pros.70104","url":null,"abstract":"<p><strong>Background: </strong>Prostate Cancer (PCa) is the second most common malignancy among men worldwide, with significant heterogeneity in disease burden across countries. The United States (US) and China, representing high socio-demographic index (SDI) countries and rapidly developing economies respectively, have distinct healthcare systems that lead to contrasting trends in PCa epidemiology. A systematic comparison of the PCa burden between the two nations from 1990 to 2021, based on the latest Global Burden of Disease (GBD) database 2021, remains limited.</p><p><strong>Methods: </strong>Data on age-standardized incidence rate (ASIR), prevalence rate (ASPR), mortality rate (ASMR), and disability-adjusted life years (ASDR) of PCa were extracted from the GBD 2021 database. Joinpoint regression and estimated annual percent change (EAPC) analyses were performed to evaluate time trends. Das Gupta's decomposition method was used to quantify the relative contributions of population growth, aging and epidemiological changes on the PCa burden. Comparative analyses focused on age-specific differences between the US and China.</p><p><strong>Results: </strong>From 1990 to 2021, Global ASIR increased from 13.69 (12.96-14.19) to 15.37 (14.13-16.25) per 100,000; the US ASMR fell from 10.85 to 6.91 (EAPC - 1.83) while China's ASIR rose from 2.04 to 4.22 (EAPC + 2.20). The aging population accounts for 74.49% of new cases and 214.72% of cancer deaths in the US, compared to 46.62% of new cases and 79.02% of deaths in China. In the US, age-specific incidence rates offset 32.44% of new cases, while in China, 31,610 new cases-representing 42.23%-were attributed to age-specific rates. The divergent magnitude, age distribution, and trajectory of PCa burden between the two countries underscore the urgent need for country-specific strategies.</p><p><strong>Conclusion: </strong>The PCa burden in the US and China has evolved in markedly different directions over the past three decades, reflecting profound impact in screening strategies and population aging. High SDI countries should refine risk-based screening protocols and management strategies. Meanwhile, China and other low and middle SDI countries must expand early, targeted screening for high-risk populations and strengthen primary healthcare to mitigate the growing burden.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"451-463"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145656429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Pubovesical Complex-Sparing Laparoscopic Radical Prostatectomy Improves Early Urinary Continence Without Compromising Oncologic Safety: A Prospective, Randomized, and Double-Blinded Clinical Trial.","authors":"Rafael Batista Rebouças, Matheus da Costa Souto, Ana Luiza Jácome Franca Campos, Rodrigo Campos Monteiro, Alcides de Assis Lira Neto, Cesar Araújo Britto, Patrícia Candido, Poliana Romão, Alberto Azoubel Antunes, William C Nahas, Sabrina T Reis, Carlo Camargo Passerotti","doi":"10.1002/pros.70106","DOIUrl":"10.1002/pros.70106","url":null,"abstract":"<p><strong>Background: </strong>Post-prostatectomy urinary incontinence significantly impacts quality of life. Techniques that preserve periprostatic structures have shown promise in promoting earlier continence recovery, particularly with robotic-assisted surgery. The study aimed to evaluate the effect of pubovesical complex (PVC) preservation on urinary continence recovery in patients undergoing laparoscopic radical prostatectomy (LRP).</p><p><strong>Methods: </strong>In this randomized, blinded, prospective clinical trial, 72 patients with localized prostate cancer were assigned to standard LRP or LRP with PVC preservation. The primary endpoint was urinary continence recovery, defined as complete absence of leakage or pad use, assessed at 24 h, 15 days, 1, 3, and 6 months post-catheter removal. Secondary endpoints included operative time, blood loss, complications, and oncologic outcomes.</p><p><strong>Results: </strong>At 6 months, continence was significantly higher in the PVC group (82.4% vs. 57.6%; p = 0.027). Earlier timepoints showed improved, though not statistically significant, continence rates in the PVC group. Operative time (109 vs. 75 min; p < 0.001) and blood loss (365 vs. 247 ml; p = 0.010) were greater with PVC preservation. Complication and margin positivity rates were similar between groups.</p><p><strong>Conclusion: </strong>PVC preservation during LRP significantly improves urinary continence recovery without compromising oncologic safety. This accessible technique can be adopted in centers lacking robotic platforms, offering equitable benefits for patients in resource-limited settings.</p><p><strong>Trial registration: </strong>Brazilian Clinical Trials Registry (ReBEC), RBR-7f25wsz.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"475-480"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"EXPRESSION OF CONCERN: Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells.","authors":"","doi":"10.1002/pros.70120","DOIUrl":"10.1002/pros.70120","url":null,"abstract":"<p><strong>Expression of concern: </strong>C. Liu, Y. Zhu, W. Lou, N. Nadiminty, X. Chen, Q. Zhou, X. B. Shi, R. W. deVere White, and A. C. Gao, \"Functional p53 Determines Docetaxel Sensitivity in Prostate Cancer Cells,\" The Prostate 73, no. 4 (2013): 418-427, https://doi.org/10.1002/pros.22583. This Expression of Concern is for the above article, published online on 19 September 2012 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Dr. Samuel Denmeade; and Wiley Periodicals LLC. A third party reported that the GAPDH band had been duplicated between Figures 4 A and 5B. This duplication was confirmed by the publisher. The authors responded to an inquiry by the publisher and stated that the GAPDH band in Figure 5B was inadvertently misplaced and duplicated from Figure 4 A. The authors also supplied images and data related to Figures 4 and 5. An evaluation of this data could not confirm that the corrected image for the GAPDH band in Figure 5B corresponded to data collected from the original experiments. This Expression of Concern has been agreed to because the journal is not able to validate some experimental data for Figures 4 and 5. The authors disagree with the Expression of Concern.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"509"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145913781","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Beyond Baseline: Serial PSA Measurements and Risk Stratification for Prostate Cancer.","authors":"Anwar E Ahmed, Bassam Dahman","doi":"10.1002/pros.70101","DOIUrl":"10.1002/pros.70101","url":null,"abstract":"","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"505-507"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12842841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145656405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NOTIFICATION: RhoGDIα Downregulates Androgen Receptor Signaling in Prostate Cancer Cells.","authors":"","doi":"10.1002/pros.70121","DOIUrl":"10.1002/pros.70121","url":null,"abstract":"<p><p>NOTIFICATION: \"RhoGDIα Downregulates Androgen Receptor Signaling in Prostate Cancer Cells,\" by Y. Zhu, C. Liu, R. Tummala, N. Nadiminty, W. Lou, and A. C. Gao, The Prostate 73, no. 15 (2013): 1614-1622, https://doi.org/10.1002/pros.22615. This Notification is for the above article, published online on 06 August 2013 in Wiley Online Library (wileyonlinelibrary.com), and has been issued by agreement between the journal Editor-in-Chief, Dr. Samuel Denmeade; and Wiley Periodicals LLC. A third party reported that the cytoplasmic Pol II band and nuclear tubulin bands in Figure 4C had been duplicated. An investigation by the publisher also found that the RhoGDIα and Tubulin bands were duplicated between Figure 2D and Figure 2E. The authors responded to an inquiry by the publisher and reported that the authors used the same images in Figure 2D and 2E to show that RhoGDIa expression was knocked down by shGDI, as the same materials were used for Fig. 2E and 2D. The editors agreed with this statement and confirmed that the Pol II and tubulin bands in Figure 4C were intentionally marked with blank images and that the same blank image had been used to illustrate that Pol II and tubulin were used as loading controls for nuclear and cytoplasmic proteins, respectively. As such, the journal's investigation has determined that there are no concerns regarding the duplicated bands in Figures 2 and 4. This Notification has been agreed to in order to inform and alert readers of the investigation.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"510"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907271","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic Testing Among Black and White Patients With Advanced Prostate Cancer: A Retrospective Analysis of Testing Utilization and Referral Patterns.","authors":"Kyle C McElyea, James P Purtell, Avery K Supernois, Courtney M Rose, Farhan Ibrahim, Mohammed A Baseer, Sunita Ghosh, Clara Hwang","doi":"10.1002/pros.70103","DOIUrl":"10.1002/pros.70103","url":null,"abstract":"<p><strong>Purpose: </strong>Genetic testing is recommended but underutilized in advanced prostate cancer. Given known disparities affecting Black patients, we assessed genetic testing completion rates by race.</p><p><strong>Methods: </strong>Henry Ford Health's electronic medical record was queried for new prostate cancer diagnoses (1/1/2017-6/30/2022). The primary outcome was completion of somatic and/or germline testing in stage IV cases. Secondary outcomes included genetic counseling referrals and attendance. Multivariable logistic regression assessed associations with baseline variables. Kaplan-Meier analysis was used for exploratory survival comparisons.</p><p><strong>Results: </strong>Among 452 stage IV patients (150 Black, 302 White), Black patients had higher somatic (30.7% vs. 18.9%, p = 0.00489) and comparable germline testing rates (16.7% vs. 21.2%, p = 0.255). In M1 cases (N = 297), germline testing was lower among Black patients (14.8% vs. 25.4%, p = 0.0329) despite higher referral rates (32.0% vs 22.2%, p = 0.0241) and similar counseling attendance (45.8% and 43.3%, p = 0.786). No significant racial differences were seen in germline testing for N1 cases (N = 155, 21.4% vs 14.2%, p = 0.274), or somatic testing for M1 (36.1% vs 25.9%, p = 0.0644) or N1 (16.7% vs 7.1%, p = 0.0728) subgroups. M1 patients that completed testing had improved survival (p = 0.0352), while no survival difference by testing in N1 disease or race was observed.</p><p><strong>Conclusions: </strong>Genetic testing uptake in this advanced prostate cancer cohort was low overall. Notably, Black patients had higher rates of somatic testing, an equitable finding given historically higher prostate cancer-specific mortality. Germline testing was comparable overall but remained lower among Black patients with metastatic disease, indicating that additional decisional and systemic barriers persist beyond access to care and referrals to genetic counseling. Insurance disparities and lower census tract-estimated income represent the largest structural differences between cohorts, with observed equity likely supported by broad coverage of commercial testing. Together, these results indicate that equitable testing utilization is achievable through consistent access frameworks, while residual disparities in germline testing warrant targeted intervention at both the patient and healthcare delivery levels.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"440-450"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145702621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Megalin (LRP2) Expression Patterns in Prostate Cancer Stem Cells and Metastatic Subtypes: Implications for Tumor Progression and Metabolism.","authors":"Gunel Mukhtarova, Aysegul Murat, Cigir Biray Avci, Eda Acikgoz, Huseyin Aktug, Gulperi Oktem","doi":"10.1002/pros.70105","DOIUrl":"10.1002/pros.70105","url":null,"abstract":"<p><strong>Background: </strong>Megalin (LRP2) is a multifunctional endocytic receptor whose role in prostate cancer (PCa), particularly in cancer stem cells (CSCs) and metastatic progression, remains largely unexplored.</p><p><strong>Methods: </strong>We analyzed LRP2 mRNA and protein expression in DU-145, PC-3, and RWPE1 cells and their CD133^high/CD44^high CSCs via qRT-PCR and immunofluorescence, in both 2D and 3D cultures. Public RNA-seq data (TCGA, WCDT-MCRPC) were used to assess LRP2, CD133, and CD44 across normal, primary, and metastatic tumors. Gene Set Enrichment Analysis (GSEA) and correlation with AR, VDR, and stemness genes were performed.</p><p><strong>Result: </strong>LRP2 was significantly upregulated in DU-145 cells and CSCs in the 3D culture system. In contrast, PC-3 CSCs showed reduced LRP2 expression. In clinical datasets, LRP2 was highest in metastatic tumors (log2FC = 3.58), with bone (M1B) and other parts of the body (M1C) subtypes exhibiting elevated levels compared to primary tumors. CD133 was consistently downregulated in metastases. GSEA highlighted LRP2 involvement in lipid, retinoid, and steroid metabolism. LRP2 correlated positively with VDR and negatively with AR in M1C tumors.</p><p><strong>Conclusion: </strong>LRP2 shows subtype-specific expression patterns in PCa, with elevated levels in DU-145 CSCs and metastatic tumors. Its link to metabolic pathways and inverse relationship with AR suggest a potential role in therapy resistance and metastasis.</p>","PeriodicalId":54544,"journal":{"name":"Prostate","volume":" ","pages":"464-474"},"PeriodicalIF":2.5,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145670813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}